Special populations

被引:13
|
作者
Zohar, Joseph [1 ]
Fostick, Leah
Black, Donald W.
Lopez-lbor, Juan J.
机构
[1] Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Psychiat, IL-52621 Tel Hashomer, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Psychiat, Tel Aviv, Israel
[4] Univ Iowa Lucille, Iowa City, IA USA
[5] Univ Iowa, Coll Med, Iowa City, IA USA
[6] Univ Complutense Madrid, Madrid, Spain
[7] Inst Psychiat & Mental Hlth, Madrid, Spain
关键词
D O I
10.1017/S1092852900002492
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Obsessive-compulsive disorder (OCD) is a formidable public health problem, rated by the World Health Organization as one of the top 20 most disabling diseases. The shame and secrecy associated with OCD, as well as the lack of recognition of its characteristic symptoms, particularly by primary care physicians, hinders appropriate diagnosis and treatment. Most adults with OCD report a late adolescent or early adulthood onset, yet OCD can occur throughout the life span. Pre-school children have been known to develop the disorder, as have elderly persons. OCD can cause considerable distress and disability; for example, children may fall behind in their education, and adults can become housebound. Comorbid psychiatric disorders have become an area of intense interest. Comorbid depression for example, is frequently the symptom that leads the individual to seek treatment. Patients with schizophrenia frequently develop obsessions and compulsions, and these symptoms are associated with a poorer outcome. The role of second-generation antipsychotics merits further study in the treatment of this subset of patients. An important step toward delineating specific subgroups within the OCD-schizophrenia axis may be the use of endophenotypic markers. Unfortunately, many patients with OCD will have a less than optimal treatment response. Poor treatment response is associated with serious social disability, but there are few clues to guide clinicians in predicting treatment response in patients with OCD, in terms of specific demographic variables, clinical symptoms, or the presence of comorbid psychiatric disorders.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [31] TRIALS IN SPECIAL POPULATIONS
    WALSON, PD
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (07): : 719 - 719
  • [32] Migraine in special populations
    Silberstein, SD
    Capobianco, DJ
    Dodick, DW
    NEUROLOGY, 2003, 60 (07) : S50 - S57
  • [33] Trials in special populations
    Weintraub, M
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (09): : 657 - 657
  • [34] Special populations in the community
    Hilton, JJ
    FAMILY & COMMUNITY HEALTH, 2000, 23 (03) : 85 - 85
  • [36] Hypertension in special populations
    Flack, JM
    Peters, R
    Nasser, SA
    CURRENT PROBLEMS IN CARDIOLOGY, 2003, 28 (02) : 194 - 223
  • [37] Trials in special populations
    Conner, JD
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1998, 59 (02): : 129 - 129
  • [38] MENTORING SPECIAL POPULATIONS
    Whitfield, K. E.
    Edwards, C. L.
    GERONTOLOGIST, 2009, 49 : 42 - 42
  • [39] Epidemiology/Special Populations
    Hayder, Salih Al-Edan
    JOURNAL OF CLINICAL HYPERTENSION, 2013, 15
  • [40] Pharmacokinetics in special populations
    Poggesi, Italo
    Benedetti, Margherita Strolin
    Whomsley, Rhys
    Le Lamer, Sophie
    Molimard, Mathieu
    Watelet, Jean-Baptiste
    DRUG METABOLISM REVIEWS, 2009, 41 (03) : 422 - 454